about
Constitutive activation of the Wnt canonical pathway in mantle cell lymphomaTruncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphomaKi67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science studyIrradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1.Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma.Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation.A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cellsHDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaDistinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometryCell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes.Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survivalCyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activitiesFluorescence PCR quantification of cyclin D1 expression.Novel targeted therapies for mantle cell lymphomaCell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma.FNC efficiently inhibits mantle cell lymphoma growth.Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphomaSpecific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.Nodal aggressive B-cell lymphomas: a diagnostic approachDual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.Synchronous adenocarcinoma and mantle cell lymphoma of the stomach.Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature.Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden.Radioimmunotherapy in mantle cell lymphoma.Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival.Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.Intestinal mantle cell lymphoma recurring at laparotomy scar region.
P2860
Q24312127-178642F4-AC41-42EA-ADEA-194E11867C14Q24655119-084AEEA1-B1CA-4256-9D26-E63E949AE5FDQ33572807-88AC374D-A668-4900-A683-8EA1E1F4C8CBQ33794602-1C90575A-5A46-4268-A201-63114D5A803FQ33828576-73766AF0-E4F2-48E3-B3A7-4B3EEB1890B6Q34188715-7796C73B-70AD-460D-A612-1E0D808BAC95Q34517533-0E554198-1B38-448A-9ABF-AAE26AF49CA4Q34813064-404D4D0C-E9AA-4F9E-AA88-BC26456D4868Q34997715-D7676077-EFE9-481B-B7D1-AB485B1B74EAQ35037756-D5602EA9-F08E-4429-BEEC-D3D7BD939389Q35134208-A6EA0EDA-F57C-4AE1-8641-C7EA2D3D0F52Q35144981-BCC788CA-A90F-4F62-BC17-0606BEBAAF06Q35483623-C52B5BE2-2F6B-4400-84D3-7F2CB6FC1745Q35809271-1C29D3D6-C8EC-4AC3-ABB7-BD4304DF2C18Q35812755-B34C0AAF-2B91-489D-BC32-8014B1280AB3Q35828800-D6CB9265-05AA-4CF5-BC72-E7EEEC5F14D5Q35848185-6FB17EC7-7828-4E6A-8BC0-FE8BD4863BA4Q35849327-A650B615-0DA4-4BEB-AFFC-348361BF1B97Q35869434-990AACCD-0ABF-4672-9DFD-1A032CB582F4Q35889841-0DE31737-6577-4400-A59A-BB4D2FA9748DQ35989467-2DCE5B4B-67F3-4FC2-9547-4346B915477EQ36216258-EE5B0E1C-F98D-40D9-9B29-6FC46F5C012FQ36315020-0900316E-9CB6-43AC-9104-E67992690AD4Q36319779-65832325-4779-46E3-8086-E0883AF34CC9Q36615459-DAAE62AF-8F3E-4F3C-A4CE-34FFB91AD435Q36629194-565DAC57-6A19-4E83-9E05-2B7366C6F879Q36763463-9E6260A5-B580-4E69-818D-E91D1D8FDE35Q36769514-DF29C733-AC71-4AD0-AE38-A1D5A8399FAAQ36957764-7DBC53C1-D156-48A5-8E86-CDA37C534410Q37065702-1BC63991-B4B2-4F90-A8E6-366690342F77Q37250153-E8EAB2B7-13F6-425F-AD83-69673E9CDC83Q37273485-A73C89D8-16E9-474D-8BF7-5C09B937B3E6Q37320512-DE2E913F-9D87-45B7-90B4-1C810CA4396DQ37352773-C65457F4-03E7-4767-9ED9-AA325D3536DCQ38017790-9F23F7DB-9A51-4717-9A94-B7FEB878AFDCQ38584605-C361B3F7-AD33-4482-9AB9-E43CCA0FE047Q39509073-1F524A70-62AC-4A4A-9A2B-9C9C9D854E47Q39882401-8B10FA3A-30B0-4018-B452-6397A17CD2D6Q40280853-5F2E4856-E5C7-41C9-8948-D2C678EB5F1CQ41869716-D3C0DFAC-0BE0-4869-93F3-0811DC0318A7
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Mantle-cell lymphoma.
@ast
Mantle-cell lymphoma.
@en
type
label
Mantle-cell lymphoma.
@ast
Mantle-cell lymphoma.
@en
prefLabel
Mantle-cell lymphoma.
@ast
Mantle-cell lymphoma.
@en
P2093
P1476
Mantle-cell lymphoma.
@en
P2093
P304
P577
1999-04-01T00:00:00Z